Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors

[1]  P. Philip,et al.  Phase I Study of Bryostatin 1 and Gemcitabine , 2006, Clinical Cancer Research.

[2]  John D. Roberts,et al.  Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma , 2006, Clinical Cancer Research.

[3]  S. Baker,et al.  Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry. , 2005, Analytical biochemistry.

[4]  H. Grunicke,et al.  Role of protein kinases in antitumor drug resistance , 2005, Annals of Hematology.

[5]  J. Soh,et al.  PKC-η mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways , 2004, Oncogene.

[6]  C. Runowicz,et al.  Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[7]  D. A. Foster,et al.  The enigmatic protein kinase Cδ: complex roles in cell proliferation and survival , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  J. Winston,et al.  Altered expression and localization of PKC eta in human breast tumors , 2001, Breast Cancer Research and Treatment.

[9]  A. Kraft,et al.  A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  A. Zeleniuch‐Jacquotte,et al.  Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  I. Pollack,et al.  Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. , 1996, Journal of neurosurgery.

[12]  Z. Szallasi,et al.  The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. , 1996, Cancer research.

[13]  A. Harris,et al.  Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. , 1996, British Journal of Cancer.

[14]  A. Harris,et al.  Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. , 1995, British Journal of Cancer.

[15]  B. Redman,et al.  Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. , 1995, Leukemia research.

[16]  G. Jayson,et al.  A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. , 1995, British Journal of Cancer.

[17]  A. Harris,et al.  Potential for protein kinase C inhibitors in cancer therapy. , 1995, Cancer treatment and research.

[18]  F. Muggia.  Concepts, Mechanisms, and New Targets for Chemotherapy , 1995, Cancer Treatment and Research.

[19]  F. Marks,et al.  Partial purification of a type eta protein kinase C from murine brain: separation from other protein kinase C isoenzymes and characterization. , 1994, The Biochemical journal.

[20]  H. Hochster,et al.  Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Harris,et al.  Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In Vivo , 1993 .

[22]  F. Zunino,et al.  Effect of modulation of protein kinase C activity on cisplatin cytotoxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells. , 1993, Cancer letters.

[23]  P. Stern,et al.  A phase I study of intravenous bryostatin 1 in patients with advanced cancer. , 1993, British Journal of Cancer.

[24]  N. Osheroff,et al.  Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism of regulation by phosphorylation. , 1993, Biochemistry.

[25]  Y. Kitamura,et al.  Predominant expression of nPKC eta, a Ca(2+)-independent isoform of protein kinase C in epithelial tissues, in association with epithelial differentiation. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[26]  H. Grunicke,et al.  Protein kinase C modulation. , 1992, Seminars in cancer biology.

[27]  F. Marks,et al.  Protein kinase Cζ and n in murine epidermis TPA induces down‐regulation of PKCn but not PKCζ , 1992 .

[28]  J. Lazo,et al.  Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. , 1992, Cancer research.

[29]  F. Marks,et al.  Protein kinase C zeta and eta in murine epidermis. TPA induces down-regulation of PKC eta but not PKC zeta. , 1992, FEBS letters.

[30]  D. Longo,et al.  Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. , 1992, Cancer research.

[31]  D. Hallahan,et al.  Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing radiation. , 1991, Cancer research.

[32]  L. Schuchter,et al.  Successful treatment of murine melanoma with bryostatin 1. , 1991, Cancer research.

[33]  H. Grunicke,et al.  Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum (II) and Other Antitumor Agents by Inhibitors of Enzymes Involved in Growth Factor Signal-Transduction , 1991 .

[34]  S. Howell.  Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy , 1991, Springer US.

[35]  J. M. Ford,et al.  Pharmacology of drugs that alter multidrug resistance in cancer. , 1990, Pharmacological reviews.

[36]  S. Howell,et al.  Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. , 1990, The Journal of biological chemistry.

[37]  T. Bradshaw,et al.  Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. , 1989, Cancer research.

[38]  H. Grunicke,et al.  Enhancement of the antiproliferative effect of cis‐diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C , 1988, International journal of cancer.

[39]  F. Marks,et al.  Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. , 1988, Carcinogenesis.

[40]  M. Sitkovsky,et al.  Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. , 1988, Journal of immunology.

[41]  J. Clardy,et al.  Isolation and structure of bryostatin 1 , 1982 .

[42]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[43]  D. Morton,et al.  Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma. , 1979, Cancer treatment reports.

[44]  G. Vogels,et al.  Differential analyses of glyoxylate derivatives. , 1970, Analytical biochemistry.